104
Participants
Start Date
September 23, 2024
Primary Completion Date
December 31, 2026
Study Completion Date
March 31, 2027
Regorafenib 40 MG Oral Tablet
REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Local Standard of Care
In this setting there are not drugs with indication. Every site will treat patients as per their experience.
RECRUITING
Istituto Oncologico Veneto, Padua
NOT_YET_RECRUITING
Azienda Ospedaliera Universitaria Gaetano Martino, Messina
RECRUITING
"IRST Istituto Romagnolo per lo Studio dei Tumori Dino Amadori", Meldola
RECRUITING
Humanitas Cancer Center, Rozzano
RECRUITING
Ospedale San Paolo, Bari
RECRUITING
Ospedale Bellaria - AUSL Bologna, Bologna
RECRUITING
Azienda Ospedaliero Universitaria Careggi, Florence
RECRUITING
Policlinico San Martino, Genova
RECRUITING
Spedali Riuniti, Livorno
RECRUITING
Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan
RECRUITING
IRCCS Ospedale San Raffaele, Milan
RECRUITING
Ospedale del Mare, Napoli
NOT_YET_RECRUITING
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Roma
RECRUITING
IRCCS Istituto Tumori Regina Elena, Roma
NOT_YET_RECRUITING
Policlinico Umberto I - Università Sapienza Roma, Roma
RECRUITING
A.O.U. Città della Salute e della Scienza di Torino, Torino
Collaborators (1)
Bayer
INDUSTRY
Istituto Oncologico Veneto IRCCS
OTHER